Bruker Corporation (Nasdaq: BRKR), a provider of scientific instruments and high value analytical and diagnostic solutions, on Friday announced EpicIF, an innovative fluorescence signal removal technology that significantly enhances its CellScape Precise Spatial Proteomics platform.

Introduced in 2022, CellScape is known for high-resolution and high dynamic range imaging, capturing comprehensive protein expression while preserving tissue morphology. EpicIF expands compatibility with commercially available antibodies nearly tenfold and boosts throughput by up to 2x. This breakthrough maintains tissue integrity and minimises cross-reactivity through a proprietary reagent and visible light application for efficient photobleaching.

Accompanying EpicIF is the updated CellScape Navigator software, featuring an intuitive interface and simplified experiment setup.

These advancements will be showcased at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. Bruker Spatial Biology continues to offer state-of-the-art spatial solutions for life sciences, enhancing research capabilities across various biopharmaceutical applications.